谷歌浏览器插件
订阅小程序
在清言上使用

Renal Denervation for Hypertension: the Current Landscape and Future Directions

HEART INTERNATIONAL(2024)

引用 0|浏览2
暂无评分
摘要
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the US population; however, recent estimates suggest that over 40% continue to have uncontrolled HTN. In the past decade, multiple placebo-controlled randomized studies have shown the safety and efficacy of renal denervation as an adjunctive therapy, culminating in the recent approval of two devices by the US Food and Drug Administration (FDA). These devices use either radiofrequency or ultrasound energies to ablate the perivascular sympathetic nerves in the renal arteries and have been shown to reduce blood pressure. In this immediate post-FDA approval era, there are still multiple issues regarding the future of the technology in its applications and reimbursement landscapes.
更多
查看译文
关键词
Blood pressure,cardiovascular disease,hypertension,intervetional cardiology,renal denervation,vascular medicine
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要